Inventor · disambiguated record
Thomas John Van Blarcom
Also filed as: VAN BLARCOM THOMAS · VAN BLARCOM THOMAS JOHN
23 granted patents·16 pending applications·105 citations·filing 2014–2024
94Inventor score
Top patents by PatentIndex Score
39 records- 0196US11814435B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Nov 14, 2023·5 cites·7 claims
- 0296US9969809B2Therapeutic antibodies and their usesPFIZER·Filed 2016·Granted May 15, 2018·44 cites·8 claims
- 0395US11155630B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Oct 26, 2021·3 cites·14 claims
- 0493US11673953B2DLL3 targeting chimeric antigen receptors and binding agentsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·9 cites·31 claims
- 0592US11377500B2Antibodies specific for CD70 and their usesPFIZER·Filed 2019·Granted Jul 5, 2022·8 cites·36 claims
- 0692US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 0791US10793635B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 0889US10040860B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Aug 7, 2018·6 cites·8 claims
- 0985US11396551B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2019·Granted Jul 26, 2022·2 cites·47 claims
- 1085US2024018252A1Therapeutic antibodies and their usesPFIZER·Filed 2023·Application pending·0 cites
- 1182US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 1281US11702474B2Antibodies specific for CD47, PD-L1, and uses thereofPFIZER·Filed 2020·Granted Jul 18, 2023·1 cites·27 claims
- 1381US9248189B2Anti-glucagon receptor antibodies and pharmaceutical compositions thereofRINAT NEUROSCIENCE CORP·Filed 2014·Granted Feb 2, 2016·5 cites·14 claims
- 1479US12036243B2BCMA CAR-T cells with enhanced activitiesALLOGENE THERAPEUTICS INC·Filed 2021·Granted Jul 16, 2024·1 cites·32 claims
- 1578US2025145725A1Chimeric antigen receptors targeting cd70PFIZER·Filed 2024·Application pending·0 cites
- 1678US2025011446A1Antibodies specific for cd70 and their usesPFIZER·Filed 2024·Application pending·0 cites
- 1777US2024425839A1Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1875US12152081B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2022·Granted Nov 26, 2024·0 cites·42 claims
- 1975US11987634B2Antibodies specific for CD70 and their usesPFIZER·Filed 2022·Granted May 21, 2024·0 cites·33 claims
- 2075US2025230410A1Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2174US12104188B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2022·Granted Oct 1, 2024·0 cites·35 claims
- 2273US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 2372US2025051421A1Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2470US2024016846A1Chimeric cytokine receptors bearing a pd-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2568US12215347B2Chimeric antigen receptors with enhanced signaling and activities and uses thereofALLOGENE THERAPEUTICS INC·Filed 2021·Granted Feb 4, 2025·0 cites·12 claims
- 2668US11326156B2Modified caspase-9 polypeptides and methods of use thereofALLOGENE THERAPEUTICS INC·Filed 2018·Granted May 10, 2022·0 cites·17 claims
- 2767US2025333719A1Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2866US2024124591A1Antibodies Specific for CD47, PD-L1, and Uses ThereofPFIZER·Filed 2023·Application pending·0 cites
- 2966US2024101710A1B-cell maturation antigen (bcma) anti-idiotypic antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3063US2024228639A1Cd70 anti-idiotype antibodiesALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3162US2024216430A1Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereofALLOGENE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3261US12404315B2Protease-activating CD45-gate CARALLOGENE THERAPEUTICS INC·Filed 2021·Granted Sep 2, 2025·0 cites·35 claims
- 3361US12043655B2Constitutively active chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2020·Granted Jul 23, 2024·0 cites·39 claims
- 3461US11786553B2Chimeric cytokine receptors bearing a PD-1 ectodomainALLOGENE THERAPEUTICS INC·Filed 2020·Granted Oct 17, 2023·0 cites·33 claims
- 3560US2022409665A1Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistenceALLOGENE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3655US12163169B2Inducible chimeric cytokine receptorsALLOGENE THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·0 cites·8 claims
- 3748US2020399343A1Improved t cell compositions and methodsALLOGENE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3841US2016311912A1Anti-glucagon receptor antibodies and methods of use thereofRINAT NEUROSCIENCE CORP·Filed 2015·Application pending·0 cites
- 3940US2023192839A1Antibodies having conditional affinity and methods of use thereofPFIZER·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas John Van Blarcom files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →